Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Solid Tumor 1Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 8Bevacizumab 8toripalimab 7senaparib 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Gemcitabine 5Fluorouracil 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorodeoxyglucose F18 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumor × LY2510924 × Clear all
NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
9 enrolled 13 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡